Cypherpunk Technologies Inc

CYPHNASDAQ · USD
1.93USD+0.06 (+2.95%)
2610

Cypherpunk Technologies Inc (CYPH) Historical Volatility

CYPH's 30 day historical volatility is 165.85%, in the 56th percentile of readings over the past year. This is an average percentile, meaning Cypherpunk Technologies Inc shares have moved roughly in line with their typical range. CYPH's 30 day implied volatility sits at 164.82%, with an IV Rank of 11.51%, leaving IV 1.03 points below historical volatility. This means options are pricing in less movement than the stock has actually delivered, as of Nov 13, 2026.

Read more

Tracking CYPH historical volatility helps you see how much Cypherpunk Technologies Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, CYPH's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor CYPH 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. CYPH's 30 day historical volatility, or CYPH HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing CYPH's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.

Historical Volatility

HV Percentile
56thHV Percentile
Moderate

Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.

Historical Volatility (30d)165.85%

HV Percentile56th

Implied Volatility (30d)164.82%

IV Rank11.51%

IV Minus HV-1.03%

As of Nov 13, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 13, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →